Cargando…

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report

BACKGROUND: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been desc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeimy, Samira, Basharat, Pari, Lovegrove, Fiona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756/ https://www.ncbi.nlm.nih.gov/pubmed/30675173 http://dx.doi.org/10.1186/s13223-019-0319-4

Ejemplares similares

A dermatomyositis/lichen planus overlap syndrome presenting with erythroderma: A case report
por: Ali, Asma Amir, et al.
Publicado: (2019)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report
por: Sui, Haijing, et al.
Publicado: (2022)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Omalizumab as a new therapeutic approach for children with severe asthma
por: Jerzyńska, Joanna, et al.
Publicado: (2014)

Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2014)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis
por: Arasi, Stefania, et al.
Publicado: (2016)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective
por: Jeimy, Samira, et al.
Publicado: (2018)

Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome
por: JESENAK, MILOS, et al.
Publicado: (2020)

Successful management of severe asthma in a young boy with eosinophilic chronic rhinosinusitis who received omalizumab: a case report
por: Shoda, Yasuho, et al.
Publicado: (2019)

Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis
por: Tsuge, Mitsuru, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab
por: Okude, Azusa, et al.
Publicado: (2012)

Omalizumab induced Takotsubo syndrome: case report
por: Aguiar-Ricardo, Inês, et al.
Publicado: (2019)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Is Omalizumab a Problem-Solving Remedy in Severe Asthma?
por: Kim, Doh Hyung, et al.
Publicado: (2018)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
por: Uzer, Fatih, et al.
Publicado: (2018)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Tozinameran: Dermatomyositis: case report
Publicado: (2022)

Omalizumab in recurring larynx angioedema: a case report
por: Ozturk, Ayse Bilge, et al.
Publicado: (2014)

Omalizumab for Urticarial Vasculitis: Case Report and Review of the Literature
por: Ghazanfar, Misbah Nasheela, et al.
Publicado: (2015)

The Bee Sting That Was Not: An Unusual Case of Hymenoptera Anaphylaxis Averted in a Patient Treated with Omalizumab for Asthma
por: Slaughter, Evelyn M., et al.
Publicado: (2014)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
por: Giovannini, Mattia, et al.
Publicado: (2019)

The complexities of insulin allergy: a case and approach
por: Aberumand, Babak, et al.
Publicado: (2021)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

Dermatomyositis associated with adenocarcinoma of the lung: A case report
por: Palakkuzhiyil, Naseem, et al.
Publicado: (2019)

Dermatomyositis associated with malignancy: A report of 3 cases
por: Tambe, Swagata A., et al.
Publicado: (2013)

Severe Thrombocytopenia in Patient with Dermatomyositis
por: TUDORANCEA, A.D., et al.
Publicado: (2018)

Treatment of severe cow’s milk allergy with omalizumab in an adult
por: Klein, Benjamin, et al.
Publicado: (2023)

Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report
por: Cherrez-Ojeda, Ivan, et al.
Publicado: (2018)

Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report
por: Stelmach, Iwona, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dhap5eaofgs6dj27o0to2gc7bn